Refine
Year of publication
Document Type
- Doctoral Thesis (5587) (remove)
Language
- German (3551)
- English (2007)
- French (9)
- Latin (5)
- Spanish (5)
- Portuguese (4)
- Italian (3)
- Multiple languages (2)
- mis (1)
Has Fulltext
- yes (5587)
Is part of the Bibliography
- no (5587)
Keywords
- Deutschland (15)
- Gentherapie (14)
- HIV (13)
- Apoptosis (12)
- Membranproteine (12)
- NMR-Spektroskopie (11)
- RNA (11)
- RNS (10)
- Nanopartikel (9)
- Proteomics (9)
Institute
- Medizin (1466)
- Biowissenschaften (813)
- Biochemie und Chemie (723)
- Physik (581)
- Pharmazie (329)
- Biochemie, Chemie und Pharmazie (285)
- Geowissenschaften (138)
- Neuere Philologien (114)
- Gesellschaftswissenschaften (110)
- Psychologie (97)
The cones of nonnegative polynomials and sums of squares arise as central objects in convex algebraic geometry and have their origin in the seminal work of Hilbert ([Hil88]). Depending on the number of variables n and the degree d of the polynomials, Hilbert famously characterizes all cases of equality between the cone of nonnegative polynomials and the cone of sums of squares. This equality precisely holds for bivariate forms, quadratic forms and ternary quartics ([Hil88]). Since then, a lot of work has been done in understanding the difference between these two cones, which has major consequences for many practical applications such as for polynomial optimization problems. Roughly speaking, minimizing polynomial functions (constrained as well as unconstrained) can be done efficiently whenever certain nonnegative polynomials can be written as sums of squares (see Section 2.3 for the precise relationship). The underlying reason is the fundamental difference that checking nonnegativity of polynomials is an NP-hard problem whenever the degree is greater or equal than four ([BCSS98]), whereas checking whether a polynomial can be written as a sum of squares is a semidefinite feasibility problem (see Section 2.2). Although the complexity status of the semidefinite feasibility problem is still an open problem, it is polynomial for fixed number of variables. Hence, understanding the difference between nonnegative polynomials and sums of squares is highly desirable both from a theoretical and a practical viewpoint.
The application of natural products (NPs) as drugs and lead compounds has greatly improved human health over the past few decades. Despite their success, we still need to find new NPs that can be used as drugs to combat increasing drug resistance via new modes of action and to develop safer treatments with less side effects.
Entomopathogenic bacteria of Xenorhabdus and Photorhabdus that live in mutualistic symbiosis with nematodes are considered as promising producers of NPs, since more than 6.5% of their genomes are assigned to biosynthetic gene clusters (BGCs) responsible for production of secondary metabolites. The investigation on NPs from Xenorhabdus and Photorhabdus can not only provide new compounds for drug discovery but also help to understand the biochemical basis involved in mutualistic and pathogenic symbiosis of bacteria, nematode host and insect prey.
Nonribosomal peptides (NRPs) are a large class of NPs that are mainly found in bacteria and fungi. They are biosynthesized by nonribosomal peptide synthetases (NRPSs) and display diverse functions, representing more than 20 clinically used drugs. Although a large number of NRPs have been identified in Xenorhabdus and Photorhabdus, the advanced genome sequencing and bioinformatic analysis indicate that these bacteria still have many unknown NRPS-encoding gene clusters for NRP production that are worth to explore. Therefore, this thesis focuses on the discovery, biosynthesis, structure identification, and biological functions of new NRPs from Xenorhabdus and Photorhabdus.
The first publication describes the isolation and structure elucidation of seven new rhabdopeptide/xenortide-like peptides (RXPs) from X. innexi, incorporating putrescine or ammonia as the C-terminal amines. Bioactivity testing of these RXPs revealed potent antiprotozoal activity against the causative agents of sleeping sickness (Trypanosoma brucei rhodesiense) and malaria (Plasmodium falciparum), making them the most active RXP derivatives known to date. Biosynthetically, the initial NRPS module InxA might act iteratively with a flexible methyltransferase activity to catalyze the incorporation of the first five or six N-methylvaline/valine to these peptides.
The second publication focuses on the structure elucidation of seven unusual methionine-containing RXPs that were found as minor products in E. coli carrying the BGC kj12ABC from Xenorhabdus KJ12.1. To confirm the proposed structures from detailed HPLC-MS analysis, a solid-phase peptide synthesis (SPPS) method was developed for the synthesis of these partially methylated RXPs. These RXPs also exhibited good effects against T. brucei rhodesiense and P. falciparum, suggesting RXPs might play a role in protecting insect cadaver from soil-living protozoa to support the symbiosis with nematodes.
The third publication presents the identification of a new peptide library, named photohexapeptide library, which occurred after the biosynthetic gene phpS was activated in P. asymbiotica PB68.1 via promoter exchange. The chemical diversity of the photohexapeptides results from unusual promiscuous specificity of five out of six adenylation (A) domains being an excellent example of how to create compound libraries in nature. Furthermore, photohexapeptides enrich the family of the rare linear D-/L-peptide NPs.
The fourth publication concentrates on the structure elucidation of a new cyclohexapeptide, termed photoditritide, which was produced by P. temperata Meg1 after the biosynthetic gene pdtS was activated via promoter exchange. Photoditritide so far is the only example of a peptide from entomopathogenic bacteria that contains the uncommon amino acid homoarginine. The potent antimicrobial activity of photoditritide against Micrococcus luteus implies that photoditritide can protect the insect cadaver from food competitor bacteria in the complex life cycle of nematode and bacteria.
The last publication reports a new family of cyclic lipopeptides (CLPs), named phototemtides, which were obtained after the BGC pttABC from P. temperata Meg1 was heterologously expressed in E. coli. The gene pttA encodes an MbtH protein that was required for the biosynthesis of phototemtides in E. coli. To determine the absolute configurations of the hydroxy fatty acids, a total synthesis of the major compound phototemtide A was performed. Although the antimalarial activity of phototemtide A is only weak, it might be a starting point towards a selective P. falciparum compound, as it shows no activity against any other tested organisms.
Mesenchymale Knochenmarksstammzellen (engl. Bone Marrow-Derived Mesenchymal Stem Cells (BMSCs)) sind hochproliferative multipotente Progenitorzellen mit einem hohen Regenerationspotential. Sie können aus dem Knochenmark in geschädigte Knorpelareale migrieren und dort zu Chondrozyten differenzieren. Somit können sie zur Reparatur traumatisch oder osteoarthrotisch bedingter Knorpelschäden beitragen. In verschiedenen Bereichen des Gelenks konnten zudem sympathische Nervenfasern sowie der sympathische Neurotransmitter Noradrenalin (NE) nachgewiesen werden. NE inhibiert die chondrogene Differenzierungskapazität von BMSCs und kann so zur Pathogenese der Osteoarthrose (OA) beitragen. Unbekannt ist zum derzeitigen Zeitpunkt, inwiefern NE die Proliferation von humanen BMSCs beeinflusst. Ziel unserer Studie war, den Einfluss von NE auf die Proliferationskapazität humaner BMSCs zu untersuchen und beteiligte intrazelluläre Signalwege zu identifizieren.
Zu diesem Zweck wurden BMSCs von Patienten nach stattgehabtem Gelenktrauma (Trauma BMSCs) und von Patienten mit diagnostizierter OA (OA BMSCs) untersucht. Zunächst erfolgte eine Analyse des Genexpressionsmusters der verschiedenen Adrenorezeptoren (ARs). Anschließend wurden sowohl Trauma als auch OA BMSCs mit NE in unterschiedlichen Konzentrationen sowie mit NE in Kombination mit verschiedenen AR-Antagonisten (Doxazosin (α1), Yohimbin (α2) oder Propranolol (β2)) behandelt. Die Aktivierung der AR-gekoppelten Signalwege wurde anhand der Phosphorylierung der beiden Hauptsignalwege der extrazellulären signalregulierten Kinasen 1/2 (ERK1/2) und der Proteinkinase A (PKA) via Western Blot untersucht.
Die Genexpression diverser AR-Subtypen konnte in Trauma (α2B-, α2C- und β2-AR) und OA BMSCs (α2A-, α2B- und β2-AR) nachgewiesen werden. Die Behandlung mit NE in hohen Konzentrationen führte zu einer statistisch signifikanten Inhibition der Proliferation von Trauma und OA BMSCs. Die Behandlung mit NE in niedrigen Konzentrationen hatte hingegen keinen Einfluss auf die Proliferation von Trauma und OA BMSCs. Sowohl ERK1/2 als auch PKA wurden in Trauma und OA BMSCs nach Behandlung mit NE aktiviert. Lediglich der β2-Antagonist Propranolol konnte sowohl die Effekte auf die Proliferation als auch auf die Aktivierung von ERK1/2 und PKA aufheben. Doxazosin und Yohimbin hatten hingegen keinen signifikanten Einfluss auf die Proliferation sowie die ERK1/2- und PKA-Phosphorylierung.
Unsere Untersuchungen zeigen, dass NE die Proliferation von Trauma und OA BMSCs konzentrationsabhängig inhibiert. Dieser Effekt wird vornehmlich über eine β2-AR-gekoppelte ERK1/2- und PKA-Aktivierung vermittelt. Über diesen Mechanismus kann NE das regenerative Potential von humanen BMSCs verringern und somit zur Pathogenese der OA beitragen. Über eine zielgerichtete Beeinflussung des β2-Signalweges könnten sich zukünftig neue therapeutische Optionen bei der Behandlung osteoarthrotisch oder traumatisch bedingter Knorpelschäden ergeben.
Stickstoffmonoxid (NO) ist ein gasförmiger Botenstoff, der über die Regulation des Vasotonus, die Hemmung der Thrombocytenaggregation sowie die Stimulation der Angiogenese auf die vaskuläre Homöostase einwirkt. Das wichtigste NO-produzierende Enzym im kardiovaskulären System ist die endotheliale NO-Synthase (eNOS), deren Aktivität durch posttranslationale Modifikationen wie Phosphorylierung und Acylierung, durch Interaktionen mit regulatorischen Proteinen wie Ca2 /Calmodulin und Caveolin sowie durch differentielle subzelluläre Lokalisation reguliert wird. Dabei sind die Faktoren, welche die (Trans-)Lokation der eNOS zwischen subzellulären Kompartimenten wie den Caveolae der Plasmamembran und dem Golgi-Apparat dirigieren, weitgehend unbekannt. Zur Identifizierung neuer Interaktionspartner wurde humane eNOS im "yeast two-hybrid"-System als "Köderprotein" eingesetzt und dabei das Fragment eines neuen humanen Proteins identifiziert, das vorläufig NOSTRIN (für: eNOS traffic inducer) genannt wurde. Im Rahmen der vorliegenden Arbeit gelang nun die Klonierung der kompletten NOSTRIN-cDNA, der Nachweis einer spezifischen Interaktion von eNOS und NOSTRIN in Säugerzellen sowie die Charakterisierung von NOSTRIN als Modulator der subzellulären Lokalisation und Aktivität von eNOS. Nach der kompletten Klonierung der NOSTRIN-cDNA mit Hilfe einer 5'-RACE resultierte ein offenes Leseraster von 506 Aminosäuren entsprechend einer Größe von ca. 58 kDa für NOSTRIN. Eine Datenbankrecherche zum Vergleich der NOSTRIN-Sequenz mit Sequenzen bekannter Proteinmotive ergab die Vorhersage einer N-terminalen Cdc15-Domäne sowie einer C-terminalen SH3-Domäne. Die direkte Interaktion zwischen eNOS und NOSTRIN konnte durch Copräzipitation in vivo und in vitro bestätigt werden. Weiterhin wurde nachgewiesen, dass die SH3-Domäne von NOSTRIN essentiell für die Bindung an eNOS ist. Zur Untersuchung des Einflusses von NOSTRIN auf die eNOS-Lokalisation wurden stabil transfizierte CHO-Zellen, die eNOS überexprimierten ("CHO-eNOS") eingesetzt. In der Immunofluoreszenz war eNOS vornehmlich in Assoziation mit der Plasmamembran und dem Golgi-Apparat zu sehen. Mit Hilfe des Semliki-Forest-Virussystems (SFV) wurde nun NOSTRIN transient überexprimiert; dabei zeigte sich für NOSTRIN eine vesikelartige Verteilung im Cytoplasma. Die NOSTRIN-Überexpression führte zu einer drastischen Umverteilung von eNOS, die nun in charakteristischen vesikelartigen Strukturen mit NOSTRIN colokalisierte. Die Verwendung von NOSTRIN-Konstukten, bei denen die SH3- Domäne deletiert war ("NOSTRIN.SH3"), veränderte zwar die typische NOSTRIN-Lokalisation nicht, ließ aber auch die subzelluläre Verteilung von eNOS unverändert, so dass NOSTRIN.SH3 und eNOS in unterschiedlichen zellulären Kompartimenten lokalisiert waren. Mit Hilfe der Immunofluoreszenz konnte ebenfalls eine Colokalisation von NOSTRIN und Caveolin-1, einem inhibitorisch wirkenden Interaktionspartner von eNOS, nachgewiesen werden. Die Analyse von Copräzipitationen mit NOSTRIN bzw. NOSTRIN.SH3 zeigte, dass Caveolin-1 in eNOS-unabhängiger Weise an NOSTRIN bindet, so dass ein ternärer Komplex aus NOSTRIN, eNOS und Caveolin-1 resultiert. Zur Klärung der Frage, ob NOSTRIN neben der subzellulären Lokalisation auch die Aktivität von eNOS beeinflusst, wurde die NO-Freisetzung von CHO-eNOS-Zellen analysiert. Dabei ergab sich, dass die transiente Überexpression von NOSTRIN in CHO-eNOS-Zellen die eNOS-Aktivität um 62 % im Vergleich zu Kontrollzellen reduzierte. In humanen primären Endothelzellen konnte mittels Immunoblotting und Immunofluoreszenzmikroskopie das Vorkommen von endogenem NOSTRIN sowie dessen Colokalisation mit endogener eNOS an der Plasmamembran nachgewiesen werden. Die Ergebnisse der vorliegenden Dissertation führen zur Hypothese, dass NOSTRIN als "molekulare Klammer" zwischen eNOS und Caveolin-1 dient, eine dynamische Umverteilung von eNOS innerhalb der Zelle vermittelt und damit das Enzym - direkt und/oder indirekt - inhibiert. Somit dürfte NOSTRIN als Modulator der Aktivität und Lokalisation von eNOS eine wichtige Rolle bei der Regulation der endothelialen NO-Produktion spielen.
Extracts of Boswellia serrata, also known as Indian frankincense, have been used to treat inflammatory diseases in the Indian ayurvedic medicine or Chinese traditional medicine (TCM) for over 3000 years, but the molecular mechanisms of the anti-inflammatory effects are still not well understood. It is obvious that the boswellic acids, the major compounds in the extracts, are responsible for the efficacy. This work employed a protein fishing technique to identify putative targets of boswellic acids at different stages within the inflammatory cascade. For fishing experiments, boswellic acids were immobilized to sepharose and incubated with cell lysates. After washing and boiling, fished proteins were separated by SDS-PAGE and analysed by MALDI-TOF-MS. CatG, DNA-PK and the protein kinase Akt were identified by protein pulldowns with immobilised BAs and characterised as selective and important targets for BAs with an IC50 in the range of physiologically achievable plasma levels up to 5 microM. In addition, the influence on several signal transductions by BAs was tested. Calcium influx, arachidonic acid release, platelet aggregation and TNFalpha-release were assayed to reveal further pharmacological effects of BAs. Celecoxib is a well-known selective COX-2 inhibitor that is in clinical use. In this work, it is demonstrated that celecoxib is also a highly potent direct 5-LO inhibitor. Celecoxib is used in arthritis and its gastro-intestinal side effects are reduced compared to non-selective NSAIDs. In patients with a familiar disposition to polyp forming, celecoxib reduced polyps and the incidence of colon cancer. Because of lowered leukotriene levels in patients under celecoxib therapy it was plausible to test whether celecoxib interferes with 5-LO. Here it is shown that the activity of 5-LO is inhibited in PMNL and cell-free assays with IC50 of 8 microM in intact cells, 20 microM with supplemented arachidonic acid and 30 microM in cell-free systems. Thus, celecoxib is a dual inhibitor of COX-2 and 5-LO. Since 2006, celecoxib has been approved as an orphan drug for the treatment of familial adenomatous polyposis. Aside from this indication, it could be useful for treatment of asthma and other diseases where 5-LO is implicated.
In Philadelphia Chromosome (Ph) positive ALL and CML the fusion between BCR and ABL leads to the BCR/ABL fusion proteins, which induces the leukemic phenotype because of the constitutive activation of multiple signaling pathways down-stream to the aberrant BCR/ABL fusion tyrosine kinase. Targeted inhibition of BCR/ABL by ABL-kinase inhibitors induces apoptosis in BCR/ABL transformed cells and leads to complete remission in Ph positive leukemia patients. However, a large portion of patients with advanced Ph+ leukemia relapse and acquire resistance. Kinase domain (KD) mutations interfering with inhibitor binding represent the major mechanism of acquired resistance in patients with Ph+ leukemia. Tetramerization of BCR/ABL through the N-terminal coiled-coil region (CC) of BCR is essential for the ABL-kinase activation. Targeting the CC-domain forces BCR/ABL into a monomeric conformation, reduces its kinase activity and increases the sensitivity for Imatinib. Here we show that i.) targeting the tetramerization by a peptide representing the Helix-2 of the CC efficiently reduced the autophosphorylation of both WT BCR/ABL and its mutants; ii.) Helix-2 inhibited the transformation potential of BCR/ABL independently of the presence of mutations; iii.) Helix-2 efficiently cooperated with Imatinib as revealed by their effects on the transformation potential and the factor-independence related to BCR/ABL with the exception of mutant T315I. These findings suggest that BCR/ABL harboring the T315I mutation have a transformation potential which is at least partially independent from its kinase activity. Targeted inhibition of BCR/ABL by small molecule inhibitors reverses the transformation potential of BCR/ABL. We definitively proved that targeting the tetramerization of BCR/ABL mediated by the N-terminal coiled-coil domain (CC) using competitive peptides, representing the Helix-2 of the CC, represents a valid therapeutic approach for treating Ph+ leukemia. To further develop competitive peptides for targeting BCR/ABL, we created a membrane permeable Helix-2 peptide (MPH-2) by fusing the Helix-2 peptide with a peptide transduction tag. In this study, we report that the MPH-2: (i) interacted with BCR/ABL in vivo; (ii) efficiently inhibited the autophosphorylation of BCR/ABL; (iii) suppressed the growth and viability of Ph+ leukemic cells; and (iv) was efficiently transduced into mononuclear cells (MNC) in an in vivo mouse model. The T315I mutation confers resistance against all actually approved ABL-kinase inhibitors and competitive peptides. It seems not only to decrease affinity for kinase inhibitors but to confer additional features to the leukemogenic potential of BCR/ABL. To determine the role of T315I in resistance to the inhibition of oligomerization and in the leukemogenic potential of BCR/ABL, we investigated its influence on loss-of-function mutants with regard to the capacity to mediate factor-independence. Thus we studied the effects of T315I on BCR/ABL mutants lacking functional domains in the BCR portion indispensable for the oncogenic activity of BCR/ABL such as the N-terminal coiled coil (CC), the tyrosine phosphorylation site Y177 and the serine/threonine kinase domain (ST), as well as on the ABL portion of BCR/ABL (#ABL-T315I) with or without the inhibitory SH3 (delta SH3-ABL) domain. Here we report that i.) T315I restored the capacity to mediate factor independence of oligomerization_deficient p185BCR/ABL; ii.) resistance of p185-T315I against inhibition of the oligomerization depends on the phosphorylation at Y177; iii.) autophosphorylation at Y177 is not affected by the oligomerization inhibition, but phosphorylation at Y177 of endogenous BCR parallels the effects of T315I; iv.) the effects of T315I are associated with an intact ABL_kinase activity; v.) the presence of T315I is associated with an increased ABL_kinase activity also in mutants unable to induce Y177 phosphorylation of endogenous BCR; vi.) there is no direct relationship between the ABL-kinase activity and the capacity to mediate factor_independence induced by T315I as revealed by the #ABL-T315I mutant, which was unable to induce Y177 phosphorylation of BCR only in the presence of the SH3 domain. In contrast to its physiological counterpart c-ABL, the BCR/ABL kinase is constitutively activated, inducing the leukemic phenotype. The N-terminus of c-ABL (Cap region) contributes to the regulation of its kinase function. It is myristoylated, and the myristate residue binds to a hydrophobic pocket in the kinase domain known as the myristoyl binding pocket in a process called “capping”, which results in an auto-inhibited conformation. Because the cap region is replaced by the N-terminus of BCR, BCR/ABL “escapes” this auto-inhibition. Allosteric inhibition by myristate “mimics”, such as GNF-2, is able to inhibit unmutated BCR/ABL, but not the BCR/ABL that harbors the “gatekeeper” mutation T315I. Here we investigated the possibility of increasing the efficacy of allosteric inhibition by blocking BCR/ABL oligomerization. We demonstrate that inhibition of oligomerization was able not only to increase the efficacy of GNF-2 on unmutated BCR/ABL, but also to overcome the resistance of BCR/ABL-T315I to allosteric inhibition. These results strongly suggest that the response to allosteric inhibition by GNF-2 is inversely related to the degree of oligomerization of BCR/ABL. Taken together these data suggest that the inhibition of tetramerization inhibits BCR/ABL-mediated transformation and can contribute to overcome Imatinib-resistance. The study provides the first evidence that an efficient peptide transduction system facilitates the employ-ment of competitive peptides to target the oligomerization interface of BCR/ABL in vivo. Further the data show that T315I confers additional leukemogenic activity to BCR/ABL, which might explain the clinical behavior of patients with BCR/ABL -T315I-positive blasts. In summary, our observations establish a new approach for the molecular targeting of BCR/ABL and its resistant mutants represented by the combination of oligomerization and allosteric inhibitors.
Necroptosis is an immunogenic form of programmed cell death characterized by plasma membrane accumulation of activated mixed lineage kinase domain-like (MLKL) that eventually leads to membrane disruption and release of danger-associated molecular patterns (DAMPs). Necroptotic cell death is tightly controlled by checkpoints, including compartmentalization as well as post-translational modifications (PTMs), like phosphorylation and ubiquitination of receptor-interacting protein kinase (RIPK) 1, RIPK3 and MLKL. Removal of plasma membrane-located activated MLKL via endocytosis or exocytosis can counteract necroptosis, but up till now, the exact mechanisms by which necroptosis is regulated downstream of MLKL activation and oligomerization are not fully understood.
Ubiquitination is a key post-translational modification that regulates various cellular processes including cell survival and cell death signaling via ubiquitination of RIPK1, RIPK3 and MLKL. M1-linked (linear) poly-ubiquitination is mediated exclusively by the linear ubiquitin chain assembly complex (LUBAC) which critically regulates cell fate and immune signaling via death receptors such as TNF receptor 1 (TNFR1).
In this study, we demonstrate that M1 poly-Ubiquitin (poly-Ub) increases during necroptosis which can be blocked by inhibition of LUBAC activity with the small-molecule HOIL-1-interacting protein (HOIP) inhibitor HOIPIN-8 or by loss of LUBAC catalytic subunit HOIP. Intriguingly, HOIPIN-8, as well as the HOIP inhibitor gliotoxin, and HOIP knockdown effectively prevent TNFα/smac mimetic/zVAD.fmk-induced necroptotic cell death in cells of human origin, without affecting necroptotic RIPK1 and RIPK3 phosphorylation, necrosome formation and oligomerization of phosphorylated MLKL. We demonstrate that HOIPIN-8 treatment inhibits MLKL translocation to intracellular membranes and accumulation in plasma membrane hotspots as well as MLKL exocytosis. We further confirm that HOIPIN-8 treatment suppresses necroptotic cell death in primary human pancreatic organoids (hPOs). Using time-lapse imaging and live/dead staining, we demonstrate loss of organoid structure and hPO cell death induced by smac mimetics and caspase inhibitors, thus providing a novel platform to investigate necroptosis in near physiological settings. Inhibition of LUBAC activity with HOIPIN-8 prevents hPO collapse and extends cell viability. Of note, loss of the M1 Ub-targeting deubiquitinating enzymes (DUBs) OTU DUB with linear linkage specificity (OTULIN) and cylindromatosis (CYLD) in human cell lines does not affect necroptosis induction and HOIPIN-8-mediated rescue of necroptosis. Intriguingly, inhibition of LUBAC activity with HOIPIN-8 does not block necroptotic cell death in murine cell lines.
Using massive analyses of cDNA ends (MACE)-seq-based global transcriptome analysis we confirm that necroptosis induces a pro-inflammatory cytokine profile which is dependent on LUBAC function and necroptotic signaling. Loss of LUBAC activity prevents the MLKL-dependent production and release of pro-inflammatory cytokines and chemokines.
Finally, we identify Flotillin-1 and -2 (FLOT1/2) as putative targets of necroptosis-induced M1 poly-Ub. Ubiquitin-binding in ABIN and NEMO (UBAN)-based pulldowns of M1 poly-ubiquitinated proteins revealed enrichment of FLOTs after necroptosis induction which is dependent on LUBAC activity and can be blocked with necroptosis inhibitors Nec-1s, GSK’872 and NSA, targeting RIPK1, RIPK3 and MLKL, respectively. Of note, loss of FLOT1/2 potentiates necroptosis suppression induced by LUBAC inhibition with HOIPIN-8.
Together, these findings identify LUBAC-mediated M1 poly-Ub as an important mediator of necroptosis and identify FLOTs as novel putative targets of LUBAC-mediated M1 poly-Ub during necroptosis. In addition, by modeling necroptosis in primary human organoids, we further expand the spectrum of experimental models to study necroptosis in human cellular settings.
Formulation scientists have developed a toolkit of strategies that can improve the solubility and subsequent bioavailability of poorly soluble candidates. Amorphous formulations are especially appealing due to the significant improvement in solubility the amorphous form can provide, but must be stabilized for effective performance (Timpe, 2007).
2. The Importance of Drug Polymer Interactions in Precipitation Inhibition
Polymeric “precipitation inhibitors” have seen widespread usage in the literature (Warren, 2010). The precipitation inhibition effect of polymers on precipitations is related to interference with nucleation and crystal growth (Xu, 2013). Many techniques have been reported in the literature to predict these interactions, however, they are not suitable to screening due to API and time resources required, which are not amenable to early stage pharmaceutical development.
3. Mesoporous Silica: An Emerging Formulation Technology
Mesoporous silicon dioxide has emerged in recent years as a new option for stabilizing the amorphous form. Upon impregnation of the silica with a concentrated drug solution, the drug can be molecularly adsorbed and locally and sterically confined, preventing recrystallization (Ditzinger, 2018). Upon administration of mesoporous silica formulations to the body the amorphous formulation generates supersaturation which must be stabilized using precipitation inhibitors (Guzman, 2007).
4. Co-incorporation: A New Method to Combine Precipitation Inhibitors with Mesoporous Silica
There has been no systematic study of how best to incorporate precipitation inhibitors into mesoporous silica formulations. The current standard practice involves combining inhibitors in a physical mixture with the drug-loaded silica, either by pestle and mortar or overhead stirring. Due to the lack of a defined protocol, there is uncertainty about how reliably the precipitation inhibitor is combined with the drug-loaded silica on a batch to batch basis. In this work, a novel co-incorporated formulation of glibenclamide and the precipitation inhibitor, HPMCAS, onto mesoporous silica was described. By co-incorporating the precipitation inhibitor, the formulation significantly outperformed the commonly applied simple physical blend due to the formation of drug-polymer interactions in the solid state.
5. In Silico Pharmaceutics: A New Method to Select Precipitation Inhibitors for Mesoporous Silica
An approach that can incorporate understanding of the drug-polymer interactions with a quick and efficient screening process would be very useful. The COnductor like Screening MOdel for Real Solvents (COSMO-RS) is a quantum mechanical theory, which can be used to derive thermodynamic properties of interest. (Klamt, 1993, 1995, 2003). We proposed excess mixing enthalpies of drug and polymer could be calculated using the COSMO-RS theory. This new approach was applied to screen precipitation inhibitors for three model compounds, all of which showed a strong positive correlation between the rank assigned based on the calculated free enthalpy of mixing and the overall formulation performance.
6. Conclusion
This body of work aimed to improve the processes underpinning the design and development of mesoporous silica with precipitation inhibitors. Firstly, this involved two extensive literature reviews in the area of solubility enhancement formulation technologies and precipitation inhibition. Secondly, a mechanistic rational and experimental approach was developed to improve the formulation of precipitation inhibitors with mesoporous silica, the “co-incorporation” approach significantly improved process efficiency and formulation performance. Finally, combining insights from the aforementioned review, and learnings from the mechanistic analysis of the “co-incorporation” approach, an in silico screening protocol was developed to calculate the enthalpy of interaction between drug and polymer, to identify the most optimal precipitation inhibitor for a given formulation.
Die 5 Lipoxygenase (5 LO) ist das Schlüsselenzym in der Synthese von Leukotrienen. Sie wird auf transkriptioneller und posttranskriptioneller Ebene reguliert. Die Differenzierung myeloider Zelllinien mit 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) und transformierendem Wachstumsfaktor beta (TGFbeta) führt zu einer Erhöhung der 5 LO mRNA-, Protein-Bildung und der zellulären Enzymaktivität. Hier wurde gezeigt, dass dabei reife, nicht jedoch prä-mRNA der 5 LO im Zytosol und im Zellkern stark angereichert wird und dass beide Agentien in die mRNA-Prozessierung eigreifen. Obwohl die Bindung von VDR-Retinoid-X-Rezeptor (RXR)-Heterodimeren an Bindungsstellen im 5 LO-Promotor mittels DNAseI-Footprinting und EMSAs nachgewiesen wurde, konnten Reportergene unter der Kontrolle des 5 LO-Promotors in transienten und stabilen Transfektionen durch 1,25(OH)2D3/TGFbeta nicht stimuliert werden. Offensichtlich wird die Induktion der Expression der 5 LO durch 1,25(OH)2D3/TGFbeta durch Elemente außerhalb des Promotors vermittelt. In transienten Transfektionen führte der Einbau der kodierenden Sequenz der 5 LO in Luziferase-Plasmide bei Cotransfektion von VDR/RXR zu einer 5 fachen Induktion der Reportergen-Aktivität durch 1,25(OH)2D3/TGFbeta, was durch zusätzlichen Einbau der letzten vier Introns auf eine 13-fache Erhöhung gesteigert wurde. Der VDR zeigte einen Ligand-unabhängigen Effekt. Diese Reportergen-Effekte waren promotorunabhängig und von der kodierenden Sequenz gesteuert. RT-PCR-Analyse wies auf eine Deletion von Teilen der kodierenden Sequenz im Laufe der mRNA-Prozessierung hin, was durch 1,25(OH)2D3/TGFbeta verhindert wird. Auch Cotransfektion der TGFbeta-Effektoren Smads 3/4 führte in Abhängigkeit von der kodierenden Sequenz und in geringerem Maße von der 3'-UTR und den Introns J M, aber unabhängig vom Promotor, zu einer starken Erhöhung der Reportergenaktivität. Die 5 LO-Expression wird in den untersuchten Zellen vermutlich durch posttranskriptionelle Prozesse (Splicing, mRNA-Reifung) herunterreguliert, während 1,25(OH)2D3/TGFbeta die Expression der 5 LO durch eine Gegenregulation zu erhöhen, an der Komplexe beteiligt sind, die vermutlich Smads, VDR-RXR-Dimere, andere Transkriptionsfaktoren, Coaktivatoren, RNA-Polymerase II und Splicing-Faktoren enthalten. Hyperacetylierung des 5 LO-Promoters durch Inkubation mit mit dem Histondeacetylase-Inhibitor TsA führte zu einer transkriptionellen Aktivierung. Die kodierende Sequenz (und die Introns) wirkt diesem Effekt vermutlich durch die Rekrutierung von HDACs an VDR oder Smads, die direkt oder indirekt an die kodierende Region binden, entgegen.